The combination of TNF-α neutralization and dexamethasone treatment restored the corticosteroid responsiveness in tobacco smoking mice

Yuki Nishimoto (Chiba, Japan), Yuki Nishimoto, Genki Kimura, Keitaro Ueda, Takahiro Nakaoki, Kazuhiro Ito, Yasuo Kizawa

Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Session: Airway pharmacology: drug targets and mode of action
Session type: Poster Discussion
Number: 5065
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Yuki Nishimoto (Chiba, Japan), Yuki Nishimoto, Genki Kimura, Keitaro Ueda, Takahiro Nakaoki, Kazuhiro Ito, Yasuo Kizawa. The combination of TNF-α neutralization and dexamethasone treatment restored the corticosteroid responsiveness in tobacco smoking mice. Eur Respir J 2016; 48: Suppl. 60, 5065

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Therapeutic neutralization of the matrikine PGP suppresses the development of lung emphysema in cigarette smoke exposed mice
Source: International Congress 2016 – Mechanisms of disease
Year: 2016

LATE-BREAKING ABSTRACT: MUC1 downregulation induces corticosteroid resistance in asthma’s in vitro and in vivo models
Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models
Year: 2016

Implication of interleukin-10 in the development of COPD induced by cigarette smoke exposure in mice
Source: Annual Congress 2013 –COPD: experimental biology
Year: 2013


Effects of tobacco smoke and poly IC, alone and in combination, on mouse lung pathology
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013


Assesment of the effects of tocilizumab, adalimumab and steroid in LPS induced acute lung inflammation
Source: International Congress 2016 – Airway response to infection
Year: 2016


Efficacy of dexamethasone, roflumilast and azithromycin in a murine cigarette smoke/NTHi infection model
Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections
Year: 2016

The effects of intra-nasally administered anti-inflammatory compounds in a mouse model of acute COPD exacerbations
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013

Comparison of the effects of e-cigarette vapor vs cigarette smoke on lung function and inflammation in mice
Source: International Congress 2015 – Emerging data on (e-)cigarettes and their health hazards
Year: 2015



The effects of clinically relevant reference agents in a mouse model of severe asthma
Source: International Congress 2015 – Advances in the future treatment of severe asthma
Year: 2015


Pharmacological profile and efficacy of GLPG1690, a novel ATX inhibitor for COPD treatment
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015


CHI-91040, a novel inhaled p38α inhibitor, counteracts lung inflammation induced by IL-1β in the rat
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016

Effect of MSC treatment on LPS-induced inflammation, emphysema and atherosclerosis in E3L mice
Source: International Congress 2015 – The multiple facets of stem and progenitor cells in lung health and disease
Year: 2015


Comparing the effects of orally and intranasally administered IKK2 inhibitors in a 4 day tobacco-smoke exposed model of COPD
Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways
Year: 2013

A combination of erythromycin and dexamethasone reduces inflammatory effects of exposure to cigarette smoke extract through modulation of Akt and histone deacetylase 2
Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases
Year: 2014


The anti-inflammatory effects of PF03715455 and roflumilast on both cellular and tissue inflammation in a mouse model of COPD
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013

Inhibition of lung inflammation by a protein epitope mimetic (PEM) neutrophil elastase inhibitor, POL6014, in a sub-chronic tobacco smoke (TS) model in mice
Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD
Year: 2013


Synergistic suppression of T cell-induced eosinophilia by CTLA4-Ig and glucocorticoid in murine asthma model
Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Year: 2016

Prediction of human lung PK for AZD7624, an inhaled P38 inhibitor for the treatment of COPD
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015

Pre-clinical to clinical potency of AZD7624 in LPS induced TNFa response
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015


Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study
Source: Eur Respir J 2009; 33: 1010-1017
Year: 2009